https://www.selleckchem.com/pr....oducts/tocilizumab.h
9% vs. 0.0%, P=0.02) and without cancer (7.1% vs. 2.5%, P0.001), respectively. Cancer was diagnosed in 2.2% of 1,303 unselected patients before PCI by cancer screening and in 2.0% within 1-year after PCI. Cancer was associated with a greater risk of non-cardiac death, whereas ongoing active cancer was associated with greater risk of major bleeding. ARC-HBR criteria successfully identified high-bleeding risk patients, irrespective of the presence or absence of cancer. Cancer was diagnosed in 2.2% of 1,303 unselected patients befo
إعجاب
علق
شارك
